Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 125-130

  Bendell, Johanna C ^a   Hong, David S ^b   Burris III, Howard A ^a   Naing, Aung ^b   Jones, Suzanne F ^a   Falchook, Gerald ^b   Bricmont, Patricia ^c   Elekes, Agnes ^c   Rock, Edwin P ^c   Kurzrock, Razelle ^b,d  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Dose escalation; OPB 31121; Solid tumors; STAT3

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CREATININE; OPB 31121; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLEEDING; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; HYPOMAGNESEMIA; LACTIC ACIDOSIS; LUNG EDEMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION; VOMITING;

ACIDOSIS, LACTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; COHORT STUDIES; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; FEASIBILITY STUDIES; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; SEVERITY OF ILLNESS INDEX; STAT3 TRANSCRIPTION FACTOR;

EID: 84903816370     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2480-2     Document Type: Article

References (9)

1. Calvisi DF, Ladu S, Gorden A et al (2006) Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130:1117-1128
2. Li WC, Ye SL, Sun RX et al (2006) Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 12:7140-7148
3. Brambilla L, Genini D, Laurini E et al (2013) Abstract C180: Novel small molecule inhibitors of signal transducer and activator of transcription (STAT3) for cancer treatment. Mol Cancer Ther 12:C180
4. Declaration of Helsinki. In: www.wma.net/e/ethicsunit/helsinki.htm. World Medical Association, Ethics Unit 2007
5. Englund G, Rorsman F, Ronnblom A et al (2006) Regional levels of drug transporters along human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Phar Sci 29:269-277 (Pubitemid 44602404)
6. Siegmund W, Ludwig K, Engel G et al (2003) Variability of intestinal expression of p-glycoprotein in healthy volunteers as described by absorption of talinonol from four bioequivalent tablets. J Pharm Sci 92:604-610 (Pubitemid 36258975)
7. Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127
8. Harrison C, Kiladjian J-J, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787-798
9. Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807